• 280+
    Pharmaceutical Partners
  • 150+
    Biomarker Assays
  • 300+
    Method Validations
  • 40+

Clinical Testing

Patient Testing for Precision Medicine

  • Pan solid tumor
    Meet the diverse demands from clinicians and patients, MEDx Translational Medicine (MEDx) has developed a series of solid tumor tests, including pan-cancer gene panel tests, single cancer gene panel assays, and immunohistochemistry (IHC).
  • Hematologic Malignancy
    Most recently, molecular diagnostic products using PCR and next-generation sequencing (NGS) have significantly improved the understanding of molecular mechanism of hematological malignancies, leading to the right choice of molecular targeting drugs for precision therapy for the individual patients in clinic.
  • Infectious Disease
    Infectious Disease

About MEDx

Translational Medicine

MEDx Translational Medicine Co., Ltd (simply MEDx) was founded in 2013, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd.Obtained with comprehensive technology platforms, high quality system, and strong IVD R&D experience, MEDx has become a leading innovative company in companion diagnostics and the total solution provider for precision medicine in China.

Taking advantage of the comprehensive translational platforms including genomics, proteomics, cytomics, and pathology, MEDx offers integrated solutions from biomarker discovery, target validation, molecular testing, and patient  stratification for drug clinical trials, to the IVD/CDx R&D and commercialization. With a world-class technical team and a rich IVD/CDx pipeline, MEDx collaborates with hundreds of world-renowned pharmaceutical companies.

view more >>


Welcome to visit the MEDx Booth at Medlab Middle East 2024

Time:5-8 February, 2024Address:Dubai World Trade CentreMEDx Booth No: # Z2.H19We are honored

Meet MEDx at Medlab Middle East | Dubai 2024
On series |PIK3CA gene mutation and targeted therapy

Introduction The study of cancer has been extended from single genes to macrogenes, and from sing

MEDx and illumina jointly promote gene sequencing technology to help global new drug research

In the development process of innovative drugs, the accompanying diagnosis is like a indicating lamp

MEDx's Debut at 2023 Medlab Asia & Asia Health a Complete Success

From August 16 to 18, MEDx participated in the 2023 MedLab Asia held at the IMPACT Exhibition Centre

MEDx Partners with Junshi Biosciences in the Innovative Co-Development of Companion Diagnostics

On May 22, 2023, Shanghai Junshi Biosciences Co., Ltd. (hereinafter referred to as "Junshi Bios

HRD Panel of MEDx

Homologous Recombination Repair (HRR) and Poly ADP-ribose Polymerase (PARP) Repair are two important

MEDx Obtained the Global Authorization of Abcam

MEDx announced the expansion of global cooperation with its strategic partner Abcam (AIM:ABC; NASDAQ

AI can predict brain cancer patients' survival

Credit: CC0 Public DomainNew research shows that artificial intelligence (AI) can predict whether ad

Research shows effectiveness of new technique to detect ovarian cancer marker peptides

VCU physics doctoral candidates Mohammed Almahyawi and Thomas W. Rockett demonstrate the setup of th

Combination of photonic sensors and microfluidics could detect cancer markers within 20 minutes

Study co-author and Skoltech PhD student Aleksei Kuzin posing next to a measurement stand. He is hol

CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-c

Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage in

“SNAF” Computational Tool Identifies Splicing Neoantigen Targets for Immunotherapy

A team of multidisciplinary researchers at Cincinnati Children’s and the University of Virginia has

Aberrant RBMX expression relevant for cancer prognosis and immunotherapy response

Credit: Aging (2024). DOI: 10.18632/aging.205363A new research paper titled "Aberrant R

Systematic analysis of the prognostic value and immunological function of LTBR in cancer

Validation of expression of the LTBR gene. Credit: Aging (2024). DOI: 10.18632/aging.205356A new